Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Assets (2022 - 2025)

Stoke Therapeutics has reported Other Non-Current Assets over the past 4 years, most recently at $227000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $227000.0 for Q4 2025, down 68.52% from a year ago — trailing twelve months through Dec 2025 was $227000.0 (down 68.52% YoY), and the annual figure for FY2025 was $227000.0, down 68.52%.
  • Other Non-Current Assets for Q4 2025 was $227000.0 at Stoke Therapeutics, down from $721000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for STOK hit a ceiling of $721000.0 in Q4 2024 and a floor of $227000.0 in Q4 2025.
  • Median Other Non-Current Assets over the past 4 years was $569000.0 (2022), compared with a mean of $576250.0.
  • Peak annual rise in Other Non-Current Assets hit 45.95% in 2025, while the deepest fall reached 68.52% in 2025.
  • Stoke Therapeutics' Other Non-Current Assets stood at $569000.0 in 2022, then changed by 0.0% to $569000.0 in 2023, then rose by 26.71% to $721000.0 in 2024, then plummeted by 68.52% to $227000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $227000.0 (Q4 2025), $721000.0 (Q3 2025), and $721000.0 (Q2 2025) per Business Quant data.